Background: Well characterised antineuronal antibodies (ANAbs) have been shown to be highly specific markers of neurological syndromes with a paraneoplastic aetiology. Previous reports indicate that pure motor neuron disease (MND) is rarely of paraneoplastic origin.
Objective: To screen systematically for the prevalence of well characterised paraneoplastic ANAbs in a large collective of patients with pure MND.
Methods: In a cohort of 145 patients with MND, the frequency of ANAbs was estimated by ELISA, employing recombinant antigens (HuD, Yo, Ri, CV2/CRMP5, Ma2 and amphiphysin).
Results: None of the sera revealed high antineuronal antigen reactivity. Very low reactivity was detected in only five sera, in all probability representing background activity.
Conclusion: According to these data, routine analysis for ANAbs in patients with isolated MND is not mandatory.
- ALS, amyotrophic lateral sclerosis
- ANAbs, antineuronal antibodies
- LMN, lower motor neuron
- MND, motor neuron disease
- OD, optical density
- PNS, paraneoplastic neurological syndromes
Statistics from Altmetric.com
Published Online First 21 February 2007
Ravo Diagnostika GmbH provided the recombinant antigens for this study.
Competing interests: S Rauer is a founding executive board member of Ravo Diagnostika GmbH, Freiburg, Germany.